Michael Sargent Binkley

Michael Sargent Binkley

Auto-generated profile, based on publicly available information

Michael Sargent Binkley

Stanford University School of Medicine, Stanford, California, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
SHSarah Haebe
Sarah Haebe
TSTanaya Shree
Tanaya Shree
ASAnuja Sathe
Anuja Sathe
GDGrady Day
Grady Day
DCDebra K. Czerwinski
Debra K. Czerwinski
RLRonald Levy
Ronald Levy
Tumor heterogeneity complicates biomarker development and fosters drug resistance in solid malignancies. In lymphoma, our knowledge of site-to-site heterogeneity and its clinical implications is still limited. Here, we profiled 2 nodal, synchronously acquired tumor samples from 10 patients with follicular lymphoma (FL) using single-cell RNA, B-cell receptor (BCR) and T-cell receptor sequencing, and flow cytometry. By following the rapidly mutating tumor immunoglobulin genes, we discovered that BCR subclones were shared between the 2 tumor sites in some patients, but in many patients, the disease had evolved separately with limited tumor cell migration between the sites. Patients exhibiting divergent BCR evolution also exhibited divergent tumor gene-expression and cell-surface protein profiles. While the overall composition of the tumor microenvironment did not differ significantly between sites, we did detect a specific correlation between site-to-site tumor heterogeneity and T follicular helper (Tfh) cell abundance. We further observed enrichment of particular ligand-receptor pairs between tumor and Tfh cells, including CD40 and CD40LG, and a significant correlation between tumor CD40 expression and Tfh proliferation. Our study may explain discordant responses to systemic therapies, underscores the difficulty of capturing a patient’s disease with a single biopsy, and furthers our understanding of tumor-immune networks in FL.

16 April 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MNMonica C. Nesselbush
Monica C. Nesselbush
BLBogdan A. Luca
Bogdan A. Luca
YJYoung-Jun Jeon
Young-Jun Jeon
IJIsabel Jabara
Isabel Jabara
CMCatherine B. Meador
Catherine B. Meador
MDMaximilian Diehn
Maximilian Diehn

25 June 2020 in Blood
Verified
Journal Article
Closed access
PDF file
MBMichael S. Binkley
Michael S. Binkley
MRM. Shahzad Rauf
M. Shahzad Rauf
SMSarah A. Milgrom
Sarah A. Milgrom
CPChelsea C. Pinnix
Chelsea C. Pinnix
RTRichard W Tsang
Richard W Tsang
RHRichard T. Hoppe
Richard T. Hoppe
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment for stage I-II NLPHL is undefined. We conducted a multi­center retrospective study including patients ≥16 years with stage I-II NLPHL diagnosed from 1995­2018 receiving all forms of management including radiotherapy (RT), combined modality therapy (CMT=RT+chemotherapy), chemotherapy (CT), observation after excision, rituximab and RT, and single agent rituximab (R). End points were progression­free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age 39 years, 72.3% being male, and 54.9% having stage I disease. Median follow up was 5.5 years (IQR=3.1-10.1). 5-year PFS and OS for the entire cohort were 87.1% (95%CI=83.6-90.0%) and 98.3% (95%CI=96.4-99.2%), respectively. Primary management was RT alone (n=257, 46.0%), CMT (n=184, 32.9%), CT alone (n=47, 8.4%), observation (n=37, 6.6%), rituximab and RT (n=19, 3.4%), and rituximab alone (n=15, 2.7%). 5-year PFS rates were 91.1% (95%CI=85.3-94.7%) after RT, 90.5% (95%CI=84.8-94.1%) after CMT, 77.8% (95%CI=61.3-88.0%) after chemotherapy, 73.5% (95%CI=50.6-87.0%) after observation, 80.8% (95%CI=41.0-95.1%) after rituximab and RT, and 38.5% (95%CI=14.0-62.8%) after rituximab alone. For the RT cohort but not the CMT cohort, variant immunoarchitectural pattern and number of sites>2 were associated with worse PFS (P2 (P=0.0006). OS for patients with stage I-II NLPHLwas excellent following all managements.

1 April 2016 in Seminars in Radiation Oncology
Verified
Journal Article
Closed access
SHSusan M. Hiniker
Susan M. Hiniker
LMLeslie A. Modlin
Leslie A. Modlin
CCClara Y. Choi
Clara Y. Choi
BABanu Atalar
Banu Atalar
KSKira Seiger
Kira Seiger
SSScott G Soltys
Scott G Soltys

4 October 2023 in JACC: Cardiooncology
Verified
Journal Article
Open access
HNHyunsoo Joshua No
Hyunsoo Joshua No
FGFelicia B. Guo
Felicia B. Guo
NPNatalie Jung-In Park
Natalie Jung-In Park
NKNoah Kastelowitz
Noah Kastelowitz
JRJune-Wha Rhee
June-Wha Rhee
MBMichael Sargent Binkley
Michael Sargent Binkley
Radiotherapy may cause grade ≥3 cardiac events, necessitating a better understanding of risk factors. The potential predictive role of imaging biomarkers with radiotherapy doses for cardiac event occurrence has not been studied. The aim of this study was to establish the associations between cardiac substructure dose and coronary artery calcium (CAC) scores and cardiac event occurrence. A retrospective cohort analysis included patients with locally advanced non–small cell lung cancer treated with radiotherapy (2006-2018). Cardiac substructures, including the left anterior descending coronary artery, left main coronary artery, left circumflex coronary artery, right coronary artery, and TotalLeft (left anterior descending, left main, and left circumflex coronary arteries), were contoured. Doses were measured in 2-Gy equivalent units, and visual CAC scoring was compared with automated scoring. Grade ≥3 adverse cardiac events were recorded. Time-dependent receiver-operating characteristic modeling, the log-rank statistic, and competing-risk models were used to measure prediction performance, threshold modeling, and the cumulative incidence of cardiac events, respectively. Of the 233 eligible patients, 61.4% were men, with a median age of 68.1 years (range: 34.9-90.7 years). The median follow-up period was 73.7 months (range: 1.6-153.9 months). Following radiotherapy, 22.3% experienced cardiac events, within a median time of 21.5 months (range: 1.7-118.9 months). Visual CAC scoring showed significant correlation with automated scoring (r = 0.72; P < 0.001). In a competing-risk multivariable model, TotalLeft volume receiving 15 Gy (per 1 cc; HR: 1.38; 95% CI: 1.11-1.72; P = 0.004) and CAC score >5 (HR: 2.51; 95% CI: 1.08-5.86; P = 0.033) were independently associated with cardiac events. A model incorporating age, TotalLeft CAC (score >5), and volume receiving 15 Gy demonstrated a higher incidence of cardiac events for a high-risk group (28.9%) compared with a low-risk group (6.9%) (P < 0.001). Adverse cardiac events associated with radiation occur in more than 20% of patients undergoing thoracic radiotherapy within a median time of <2 years. The present findings provide further evidence to support significant associations between TotalLeft radiotherapy dose and cardiac events and define CAC as a predictive risk factor.

5 November 2024 in JACC: Cardiooncology
Verified
Journal Article
Open access
SBSantino Butler
Santino Butler
HNHyunsoo No
Hyunsoo No
FGFelicia Guo
Felicia Guo
GMGibran Merchant
Gibran Merchant
NPNatalie J. Park
Natalie J. Park
MBMichael Sargent Binkley
Michael Sargent Binkley
Atrial fibrillation (AF) has been associated with thoracic radiotherapy, but the specific risk with irradiating different cardiac substructures remains unknown. This study sought to examine the relationship between irradiation of cardiac substructures and the risk of clinically significant (grade ≥3) AF. We analyzed data from patients who underwent definitive radiotherapy for localized cancers (non–small cell lung, breast, Hodgkin lymphoma, or esophageal) at our institution between 2004 and 2022. The 2-Gy fraction equivalent dose was calculated for cardiac substructures, including the pulmonary veins (PVs), left atrium, sinoatrial node, and left coronary arteries (the left main, left anterior descending, and left circumflex arteries). Competing risk models (subdistribution HRs [sHRs]) for AF incidence were adjusted for the Mayo AF risk score (MAFRS). Among 539 patients, the median follow-up was 58.8 months. The 5-year cumulative incidence of AF was 11.1% for non–small cell lung cancer, 8.3% for esophageal cancer, 1.3% for breast cancer, and 0.8% for Hodgkin lymphoma. Increased AF risk was associated with a higher PV maximum dose (dmax) (sHR: 1.22; P < 0.001), larger left atrial volume (sHR: 1.01; P = 0.002), greater smoking history in pack-years (sHR: 1.01; P = 0.010), and higher MAFRS (sHR: 1.16; P < 0.001). PV dmax remained a significant predictor of AF across different MAFRS subgroups (Pinteraction = 0.11), and a PV dmax >39.7 Gy was linked to a higher AF risk, even when stratified by MAFRS. PV dmax is a significant predictor of grade ≥3 AF regardless of underlying risk factors. These findings highlight the importance of cardiac substructures in radiation toxicity and suggest that various PV dose metrics should be further validated in clinical settings.